SARC was formed in 2003 by the sarcoma research community to bring together the best cancer centers and researchers in the world.  Amongst other accomplishments, SARC has completed 21 innovative clinical trials, with six more underway. SARC’s unique ability to promote collaboration and unity among the leading sarcoma researchers ensures great accomplishment.

SARC is dedicated to fostering progress in the treatment of sarcoma to improve patient outcomes, and ultimately find a cure. SARC is one of the few organizations focusing on all types of sarcoma.

Funding Opportunities »
Publications »
SARC Clinical Trials »
Tumor Board »


Microscope and vial

Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials.


Stethoscope on graphs

SARC can help you. We’re committed to helping bring together sarcoma specialists dedicated to laboratory research and clinical studies. 


SARC Biospecimen Bank

The SARC Biospecimen Bank is designed to help qualified sarcoma investigators or organizations gain access to de-identified specimens to carry out projects that may explore relevant biomarkers, identify novel therapeutic targets, or make other translational discoveries. SARC invites applications to conduct translational research using these materials.

Learn more about the SARC Biospecimen Bank.

SARC Clinical Data Repository

SARC has established a repository of clinical data sets from 12 clinical trials, including more than 1,700 patients.

Learn more about SARC Clinical Data Repository.

SARC Imaging Resources

SARC imaging data collected from two clinical trials is now available to sarcoma researchers for further query.

Learn more about SARC Imaging Resources.

NCI Formulary

We foster collaboration among investigators, academia, and pharma. The National Cancer Institute (NCI) agent formulary (NCI Formulary) is a public-private partnership between the NCI and pharmaceutical and biotechnology companies with a purpose of providing academic investigators with rapid access to agents or combinations of agents for cancer clinical trial use. Agents within the NCI Formulary are available to investigators at NCI-designated Cancer Centers for the conduct of clinical trials under investigator-held IND, as well as pre-clinical research.

Visit the NCI Formulary website to review the list of available agents

Sarcoma Drug Response Portal

The National Cancer Institute performed a screen of 100 FDA-approved compounds and 345 investigational agents in 63 human and pediatric sarcoma cell lines. Gene expression and miRNA expression is also available

See results published at NIH National Center for Biotechnology Information

Back to top